ASH: Rituxan + CHOP Improves Survival of Indolent Lymphoma in Older Patients
For older patients with follicular lymphoma, the addition of Rituxan (rituximab, MabThera) to standard CHOP chemotherapy boosted overall response rates, prolonged time to treatment failure, and improved overall survival, German researchers said at the ASH conference.
"The addition of rituximab to CHOP in treating advanced stage follicular lymphoma significantly improves the outcome of patients with previously untreated follicular lymphoma, not only in young patients, but also in patients of advanced age," said Dr. Christian Buske, M.D., of the Klinikum Grosshadern in Munich.
Follicular lymphoma is an indolent lymphoma with an incidence that rises sharply with age, Dr. Buske noted. More than 40% of patients with follicular lymphoma are older than 60 at the time of diagnosis, and there is an age-specific incidence peaking above 75.
ASH abstract #482: Buske C et al. "Front-line Combined Immuno-Chemotherapy (R-CHOP) Significantly Improves the Time to Treatment Failure and Overall Survival in Elderly Patients with Advanced Stage Follicular Lymphoma -- Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG)"
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
